Aktis Oncology (NASDAQ:AKTS) Shares Gap Down – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $19.55, but opened at $18.50. Aktis Oncology shares last traded at $18.7050, with a volume of 9,999 shares traded.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AKTS shares. HC Wainwright upped their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Leerink Partners started coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price objective for the company. Bank of America started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 price objective on the stock. TD Cowen started coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Finally, William Blair started coverage on Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Aktis Oncology Trading Up 0.5%

The company’s 50 day simple moving average is $18.65.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The firm had revenue of $1.87 million during the quarter. Analysts anticipate that Aktis Oncology will post -1.56 earnings per share for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.